Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JS203 + lenalidomide
- Development stage
- Phase 2
- Lead developer
- Junshi Biosciences
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
JS203 + lenalidomide is a combination therapy being developed by Shanghai Junshi Bioscience for the treatment of various B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). JS203 is a recombinant humanized bispecific antibody that targets CD20 on malignant B-cells and CD3 on T-cells, facilitating T-cell-mediated cytotoxicity against the tumor cells. Lenalidomide is an oral immunomodulatory drug (IMiD) that binds to the Cereblon (CRBN) E3 ubiquitin ligase complex, leading to the degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). This action results in direct anti-tumor effects and enhances the activity of immune effector cells, potentially providing a synergistic therapeutic effect when combined with the T-cell engaging mechanism of JS203.
02
Targets
CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)CK1α (Casein kinase I alpha)CRBN (Cereblon)IKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)
Beyond the preview
Go deeper on JS203 + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JS203 + lenalidomide.